Patrick Campbell
Associate Editorial Director at HCP Live
Associate Editorial Director: @HCPLiveNews. Producer: #DiabetesDialogue & #DontMissABeat Formerly: @njdotcom & @poconorecord Opinions are my own. #Ramily
Articles
-
1 week ago |
theeducatedpatient.com | Patrick Campbell
Despite frustration and difficulty with prescription costs, most Americans are hesitant to start conversations that could lead to solutions, according to a new study. A survey of 2000 American adults, results of the study indicate 75% of respondents admitted to being surprised by the cost of a medication, but 74% of respondents have never discussed financial challenges with their doctor or pharmacist.
-
2 weeks ago |
hcplive.com | Patrick Campbell
Data from the American College of Physicians Internal Medicine Meeting suggests use of steroidal mineralocorticoid receptor antagonists (MRAs) offered minimal benefit and increased the risk of hyperkalemia among patients with a history of kidney transplant.
-
2 weeks ago |
hcplive.com | Patrick Campbell
A new study from one of the nation’s leading medical centers suggests use of artificial intelligence (AI) in virtual visits could improve decision-making and adherence to guideline-directed care in virtual urgent care settings.
-
3 weeks ago |
hcplive.com | Patrick Campbell
Author(s):Fact checked by: Semaglutide showed promise in improving outcomes for peripheral artery disease and reducing cardiovascular events in type 2 diabetes patients. Dapagliflozin reduced mortality and heart failure worsening post-TAVI, supporting SGLT2 inhibitors in high-risk heart failure patients. Sotatercept significantly decreased mortality and hospitalization risks in pulmonary arterial hypertension, indicating a potential paradigm shift.
-
3 weeks ago |
hcplive.com | Patrick Campbell
The US Food and Drug Administration (FDA) has granted accelerated approval to atrasentan (Vanrafia), a once-daily, non-steroidal, oral treatment, for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression. Announced by Novartis on April 02, 2025, the decision marks the FDA’s first approval for a selective endothelin A receptor antagonist for reducing protein in IgAN—adding to nephrology’s growing armamentarium of therapies.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 715
- Tweets
- 8K
- DMs Open
- No
RT @TheEduPatient: A new heart drug, vutrisiran (Amvuttra), was just FDA-approved to treat ATTR-CM — a rare condition that stiffens the hea…
RT @TheEduPatient: For the first time in 20+ years, there’s a new class of pain medication. Suzetrigine (Journavx) treats short-term pain w…
Big news in 🧬therapy: The FDA has awarded Fast Track designation to VERVE-102 for the treatment of individuals with hyperlipidemia and high cardiovascular risk to lower LDL-C levels. More on @HCPLiveNews: https://t.co/CJ2XSqKmao #Cardiotwitter $VERV @skathire